RxSight (RXST)

• Market cap: $381M
• 1 day: -1.17%
• 5 days: 5.32%
• 1 month: 26.67%
• 3 months: -34.76%
• 6 months: -64.29%
• Year to date: -73.05%
• 1 year: -82.93%
• 5 years: -41.81%
• 10 years: -41.81%
• Sector: Healthcare
• Industry: Medical Devices

About: RxSight Inc is a commercial-stage medical technology company dedicated towards improving the vision of patients following cataract surgery. It offers intraocular lens technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery. The company operates and manages its business in one reportable segment, the research and development, manufacture and sale of light adjustable lenses and related capital equipment.

Employees: 498

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

90% more repeat investments, than reductions

Existing positions increased: 74 | Existing positions reduced: 39

0.75% more ownership

Funds ownership: 90.32% [Q1] → 91.07% (+0.75%) [Q2]

0% more funds holding in top 10

Funds holding in top 10: 1 [Q1] → 1 (+0) [Q2]

10% less funds holding

Funds holding: 192 [Q1] → 173 (-19) [Q2]

30% less first-time investments, than exits

New positions opened: 35 | Existing positions closed: 50

48% less capital invested

Capital invested by funds: $923M [Q1] → $481M (-$442M) [Q2]

88% less call options, than puts

Call options by funds: $455K | Put options by funds: $3.83M

Research analyst outlook

8 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $8
• Avg. target: $9.13
• High target: $11

8 analyst ratings

• positive: 1 13%
• neutral: 6 75%
• negative: 1 13%

UBS Danielle Antalffy	$8	Neutral Maintained	8 Aug 2025
Stifel Tom Stephan	$8	Hold Maintained	8 Aug 2025
Needham David Saxon	$11	Buy Maintained	8 Aug 2025
Morgan Stanley Patrick Wood	$9	Equal-Weight Downgraded	15 Jul 2025
Jefferies Young Li	$9	Hold Downgraded	10 Jul 2025